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Abstract
Background: Angiogenesis is an important process involved in the pathogenesis of diffuse parenchymal lung
diseases. The aim of the study was to compare the angiogenic profile of patients with sarcoidosis and idiopathic
pulmonary fibrosis (IPF) based on analysis of circulating factors.
Methods: Serum concentrations of angiopoietin-2 (Ang-2), follistatin, granulocyte-macrophage-colony stimulating
factor (GM-CSF), interleukin-8 (IL-8), platelet derived growth factor-BB (PDGF-BB), platelet endothelial cellular
adhesion molecule-1 (PECAM-1) and vascular endothelial growth factors (VEGF) were measured in the patients and
the healthy subjects.
Results: Serum concentrations of G-CSF, follistatin, PECAM-1 and IL-8 were significantly higher in the IPF patients in
comparison with the control group and the sarcoid patients. PDGF-BB concentrations were also significantly higher
in serum of IPF patients than in sarcoid patients, but not than in the controls. In contrast, Ang-2 and VEGF
concentrations did not differ significantly between the three groups. In the sarcoid patients, irrespective of the
disease activity or the radiological stage, serum concentrations of these cytokines were similar to the control group.
Conclusions: These results indicate that differences may exist in angiogenic activity between patients with
parenchymal lung diseases. In contrast to sarcoidosis, IPF is characterized by a higher serum concentration of
different molecules involved in the angiogenic processes .
Background
The interstitial lung diseases are a heterogeneous group
of diffuse parenchymal lung diseases, including sarcoid-
osis and idiopathic pulmonary fibrosis (IPF). IPF is char-
acterized by tissue damage and exuberant repair with an
aberrant wound-healing response leading to a severe dis-
ruption of the pulmonary architecture [1]. On the other
hand, sarcoidosis is a multisystem inflammatory disease
of unknown etiology that is characterized by non-
caseating epithelioid cell granulomas and the accumu-
lation of CD4-T cells and macrophages at the sites of
inflammation [2, 3].
Angiogenesis, defined as the process of growth of new
blood vessels, plays a pivotal role in wound healing and
may contribute to the fibroproliferation and extracellular
matrix deposition observed in IPF and in advanced
stages of sarcoidosis [2–5].
Among various markers of angiogenesis, angiopoietin-
2 (Ang-2), follistatin, granulocyte-macrophage-colony
stimulating factor (GM-CSF), interleukin 8 (IL-8), plate-
let derived growth factor-BB (PDGF-BB), platelet endo-
thelial cellular adhesion molecule-1 (PECAM-1) and
vascular endothelial growth factor (VEGF), seem to be
involved in different steps of physiological and patho-
logical angiogenic processes, such as proliferation, mat-
uration and survival of new blood vessels .
Ang-2, which is part of a family of vascular growth
factors that play a role in embryonic and postnatal
angiogenesis and is involved in controlling microvascu-
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signaling the smooth muscle cells surrounding vessels
[6, 7]. In addition, Ang-2 as an antagonist ligand of Tie2
receptor expressed by endothelial and hematopoietic cells,
promotes cell death and disrupts vascularization [6, 7].
Follistatin is an activin-binding protein with the function
of binding and bioneutralizing members of the transform-
ing growth factor beta (TGF-β) superfamily, with a par-
ticular focus on activin, a paracrine hormone [8]. IL-8,
known as a neutrophil chemotactic factor and produced
by macrophages, epithelial cells, airway smooth muscles
and endothelial cells, is also a potent promoter of angio-
genesis [9].
GM-CSF is a cytokine secreted by macrophages, T
cells, mast cells, NK cells, endothelial cells and fibroblasts
and it functions as a white blood cell growth factor. Add-
itionally, GM-CSF plays a vital role in angiogenesis
through the regulation of VEGF and sVEGFR-1 [10].
PDGF-BB stimulates proliferation of fibroblasts [11].
PECAM- 1 plays role in the leukocyte transmigration [12].
VEGF, which is an endothelial cell-specific mitogen that
promotes angiogenesis and is a potent mediator of vascu-
lar permeability [13, 14].
The aim of this study was to analysis serum concen-
trations of these markers associated with angiogenic
processes, rarely investigated simultaneously in patients
with IPF and sarcoidosis; looking for any possible dif-
ferences and correlations with the main clinical
parameters.
Methods
Forty three non-smoking patients with sarcoidosis and
17 non-smoking patients with IPF characterized in our
previous report [15] were enrolled in the study. Their
demografic and spirometric characteristics are shown in
Table 1. The recruitment of patients with blood serum
collection was completed in 14 months – February 2012
till March 2013. Sarcoidosis was histologically proven
according to the ATS criteria [2] (i.e., by the demonstra-
tion of non-caseating granulomas in tissue samples ob-
tained in the transbronchial lung biopsy, the lymph node
scale biopsy, mediastinoscopy, or the bronchial biopsy).
Only patients with clinical stages I - III were included in
the study. Sarcoidosis stage I is featured by hilar lymph
nodes enlargement, stage II by concomitant hilar lymph-
adenopathy and pulmonary infiltrates, whereas in stage
III only pulmonary infiltrates are visible on the chest X-
ray. Eleven patients had stage I, 20 patients had stage II,
and 12 patients had stage III of the disease [2]. Among
the patients with sarcoidosis, 18 subjects had a progres-
sive disease, i.e., progressive lymphadenopathy or inter-
stitial infiltrates with or without deterioration of the
pulmonary function tests (at least FVC or FEV1 decline
above 10 % during 3 month period before study enroll-
ment) [15]. None of the patients with sarcoidosis had
Löffgren syndrome.
Seventeen patients with IPF were diagnosed according
to the ATS criteria [1] (using the HRCT and/or lung
Table 1 Demografic and spirometric data patients with IPF and sarcoidosis
Sarcoidosis total IPF Controls
N = 43 (20 F/ 23 M) N = 17 (7 F/ 10 M) N = 20 (10 F/10 M)
(mean ± SEM) (mean ± SEM) (mean ± SEM)
Median (Interquartile range) Median (Interquartile range) Median (Interquartile range)
Age (years)
35.7 ± 1.3 58.3 ± 1.6 *** 34.3 ± 1.2
33.5 (29.5–40.0) 58.0 (53.7–64.0) 33.5 (29.5–37.5)
BMI (kg/m2) 26.9 ± 0.5 27.4 ± 0.7 27.2 ± 0.6
27.0 (23.2–31.4) 27.6 (21.2–31.3) 27.1 (22.3–30.1)
FEV1 (% of predicted)
86.1 ± 1.6 67.9 ± 2.3 **
85.5 (81.0–93.0) 69.0 (61.0–77.3)
FVC (% of predicted)
96.2 ± 2.1 70.3 ± 1.8 **
98.0 (88.5–104.0) 69.0 (63.5–79.0)
FEV1%VC (%)
75.7 1.0 77.0 ± 1.8
75.0 (71.0–80.0) 76 (73.5–82.3)
F females, M males, IPF idiopathic pulmonary fibrosis, FEV1 Forced expiratory volume in 1 s
FVC Forced Vital Capacity, FEV1%VC forced expiratory volume in one second % of vital capacity **p < 0.001 IPF vs sarcoidosis ***p < 0.001 IPF vs controls
and sarcoidosis
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biopsy). The mean duration of the disease since the
diagnosis was 3.5 years (0.5–6 years) for sarcoidosis and
1.2 year (0.5–3 years) for IPF. No study participant was
taking oral corticosteroids or immunosuppressive drugs
at the time of the enrollment to the study. None of the
patients or controls suffered from any chronic liver or
kidney disease; all participants were free from infections
for at least three months before the blood sample collec-
tion. All patients were candidates for Nordic walking re-
habilitation and were routinely controlled in the out-
patient clinic at the Department of Lung Diseases and
Tuberculosis, Silesian University of Medicine, and
underwent radiological and spirometric examinations.
Spirometry was performed using the PULM-Test 1000
spirometer (Krakow, Poland) according to the ATS/ERS
criteria [16], and the results were expressed as the per-
centage of the predicted values [17]. Twenty healthy
nonsmoking volunteers matching the sarcoid group in
terms of sex, age, and BMI served as controls.
All subjects provided written informed consent and
the study was approved by the local ethical committee at
Medical University of Silesia (number KNW/0022/KB1/
32a/12).
Analytical methods
Serum concentrations of Ang-2,follistatin, GM-CSF, IL-
8, PDGF-BB, PECAM-1 and VEGF were measured in
duplicate (the mean value from 2 measurements was de-
rived) using commercially available multiplex bead-
based sandwich immunoassay kits (Human Angiogenesis
9-Plex Panel, Bio-Rad Laboratories). All assays were per-
formed according to the manufacturer’s instructions.
The system allowed simultaneous identification of 9 dif-
ferent molecules in a 96-well filter plate. We used 9 dif-
ferent sets of fluorescent dyed beads with capture
monoclonal antibodies specific for each molecule to be
analyzed. The appropriate molecule standards (50 μl/
well) and samples diluted (50 μl/well) in plasma diluents
were added to a 96-well filter plate and incubated for
30 min. at room temperature. After 3 washes, premixed
streptavidin/phycoerythrin was added to each well and
incubated for 10 min. followed by 3 additional washes.
The beads were resuspended with 125 μl of assay buffer,
and the molecule reaction mixture was quantified via
the Bio-Plex protein array reader.
The data analysis was performed using the Bio-Plex
Manager software version 4.1.1. (Bio-Rad Laboratories).
Values with a coefficient of variation over 12 % were dis-
carded before the final data analysis. The concentration
(pg/mL) of different analytes in the plasma samples was
identified using standard curves from the multiplex assays.
The minimum level of detection for VEGF was 3.27, 11.32
for Ang-2, 5.15 for PDGF-BB, 33.29 for PECAM-1, 8.41
for follistatin, 6.66 for G-CSF and 1.6 for IL-8.
Statistical analysis
The statistical analysis was conducted using Statistica
6.0 software (StatSoft Inc., Tulsa, OK). The normal data
distribution was assessed using Shapiro-Wilk test.
Homogeneity of variance was evaluated using Levene’s
test. Comparisons between the study groups were per-
formed using the ANOVA, Mann–Whitney or Kruskal-
Wallis test, if the distribution of data was abnormal.
Correlations were analyzed by Spearman’s test. All re-
sults were statistically significant if p < 0.05.
Results
In the IPF patients in comparison with the control group
and the sarcoid patients we observed significantly higher
serum concentrations of GM-CSF, follistatin, PECAM-1
and IL-8. Serum concentrations of PDGF-BB were also
significantly higher in the IPF patients than in the sar-
coid patients but not than in the controls. In the IPF pa-
tients, serum Ang-2 and VEGF concentrations did not
differ significantly from these obtained in the sarcoid
group and the controls (Table 2 and Figs. 1, 2, 3, 4, 5, 6,
and 7). In the IPF group we found statistically significant
correlations between concentrations of Ang-2 and IL-8
(r = 0.62, P < 0.01), follistatin and PECAM-1 (r = 0.83,
P < 0.0001) and PDGF-BB and VEGF (r = 0.7, P < 0.01).
In the sarcoid patients concentrations of serum Ang-2,
follistatin, GM-CSF, IL-8, PDGF-BB, PECAM-1 and
VEGF were similar to the values noticed in the control
group. In patients with progressive and non-active (clin-
ically stable) sarcoidosis the serum concentrations of all
molecules were similar. No significant differences were
observed between stage I, II and III-only serum Ang-2
concentrations in stage I patients was significantly
higher than in stage II and III (Table 3). In the sarcoid-
osis group we found statistically significant relationships
between concentrations of Ang-2 and IL-8 (r = 0.62,
P < 0.0001), follistatin and PECAM-1 (r = 0.76, p < 0.0001)
as well as PDGF-BB and PECAM-1 (r = 0.82, p < 0.0001).
Both in the IPF group and the sarcoid group no signifi-
cant correlations between concentrations of the examined
molecules and the pulmonary function parameters (FEV1,
FVC) (Table 3).
Discussion
In our study elevated serum concentrations of IL-8,
GM-CSF, follistatin, PDGF-BB and PECAM-1 in the IPF
patients, but not in the sarcoidosis patients even in ac-
tive progressive disease have been observed. Surprisingly,
VEGF and Ang-2 concentrations (i.e., the main proan-
giogenic cytokine) both in the sarcoid and the IPF pa-
tients were similar to the concentrations observed in the
controls. We did not find any differences in serum con-
centrations of the examined cytokines obtained from pa-
tients with progressive i.e., active sarcoidosis and stable
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Table 2 The mean serum concentrations of examined cytokines in patients with IPF and sarcoidosis
Sarcoidosis n = 43 IPF n = 17 Control group n = 20
Mean ± SEM Mean ± SEM Mean ± SEM
Median (95 % CI) Median (95 % CI) Median (95 % CI)
Angiopoeitin-2 221.5 ± 28.7 251.6 ± 45.6 288.8 ± 68,9762
(pg/ml) 173.5 (120.7–301.8) 237.8 (72.1–294.6) 168.7 (95.6–360.4)
Follistatin 357.6 ± 31.9 582.5 ± 64.5** 462.7 ± 89.6
(pg/ml) 346.5 (264.7–416.1) 545.8 (418.5–674.5) 291.2 (231.5–478.3)
GM-CSF 31.7 ± 4.7 67.6 ± 6.4*** 29.5 ± 5.2
(pg/ml) 15.7 (10.5–43.1) 71.1 (41.7–86.5) 24.8 (9.3–48.2)
IL-8 30.8 ± 4.0 76.3 ± 5.2*** 28.9 ± 4.7
(pg/ml) 15.8 (13.8–39.7) 79.9 (57.9–96.3) 20.7 (11.4–46.0)
PDGF-BB 5528.3 ± 551.2 8629.8 ± 869.1# 7080.1 ± 1046.6
(pg/ml) 4607.0 (3464.6–6128.8) 7178.0 (6732.8–9948.4) 5384.1 (3173.5–10040.3)
PECAM-1 2490.4 ± 232.9 3392.1 ± 376.8* 2316.9 ± 388.9
(pg/ml) 2290.7 (1693.7–2795.2) 3147.5 (2428.6–4072.6) 1798.1 (1226.1–2563,1)
VEGF 88.7 ± 7.7 120.5 ± 16.0 78.0 ± 10.8
(pg/ml) 84.1 (61.9–95.4) 94.3 (77.6–157.2) 80.1 (32.6–109.2)
*p < 0.05 IPF vs sarcoidosis and vs control group
**p < 0.01 IPF vs sarcoidosis and vs control group
***p < 0.001 IPF vs sarcoidosis and vs control group
#p < 0.05 IPF vs sarcoidosis
Fig. 1 Individual serum concentrations of angiopoeitin-2 in patients with sarcoidosis and IPF in comparison to the control group. IPF vs sarcoidosis
and vs control group, p > 0.05
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Fig. 2 Individual serum concentrations of follistatin in patients with sarcoidosis and IPF in comparison to the control group. IPF vs sarcoidosis and
vs control group, p < 0.01
Fig. 3 Individual serum concentrations of GM-CSF in patients with sarcoidosis and IPF in comparison to the control group. IPF vs sarcoidosis and
vs control group, p < 0.001
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Fig. 4 Individual serum concentrations of IL-8 in patients with sarcoidosis and IPF in comparison to the control group. IPF vs sarcoidosis and vs
control group, p < 0.001
Fig. 5 Individual serum concentrations of PDGF-BB in patients with sarcoidosis and IPF in comparison to the control group. IPF vs
sarcoidosis, p < 0.05
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Fig. 6 Individual serum concentrations of PECAM-1 in patients with sarcoidosis and IPF in comparison to the control group. IPF vs sarcoidosis
and vs control group, p < 0.05
Fig. 7 Individual serum concentrations of VEGF in patients with sarcoidosis and IPF in comparison to the control group. IPF vs sarcoidosis and vs
control group, p > 0.05
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non-active sarcoidosis. To the best of our knowledge we
were the first to demonstrate the serum concentrations
of Ang-2, PECAM-1 and follistatin in IPF and
sarcoidosis.
Keane et al. [18, 19] demonstrated increased angio-
genic activity in a large number of IPF lung specimens
and speculated that there may be an opposing balance of
angiogenic and angiostatic factors favors angiogenesis.
However, other reports made the role of angiogenesis in
IPF controversial. Meyer et al. [20] and Koyama et al.
[21] documented depressed VEGF levels in bronchoalve-
olar lavage (BAL) from IPF patients compared to a var-
iety of diffuse parenchymal lung diseases or healthy
controls. On the other hand, a statistically significant in-
crease has been detected in VEGF mRNA expression in
BAL from IPF in comparison with pulmonary sarcoid-
osis. However, no statistically significant difference has
been measured in VEGF concentration between patients
with IPF and sarcoidosis [22].
Nevertheless, Sekiya et al. [23] demonstrated a strong
correlation between elevated serum VEGF concentra-
tions and clinical parameters of the disease activity and
severity in patients with sarcoidosis, indicating their po-
tential usefulness as a predictor of the disease extent and
the responsiveness to treatment. Our previous study [24]
revealed increased VEGF concentration in the BAL fluid
obtained from the lung regions most affected by the sar-
coid process. Tzouvelekis et al. [25], using the tissue
microarray technology, demonstrated an abundant ex-
pression of VEGF in sarcoidosis mediastinal lymph
nodes. An elevated serum concentration of IL-8 in IPF
can indicate the disease activity [26]. IL-8 was increased
and correlated with the percentage and absolute number
of neutrophils in the BAL fluid of IPF patients [27].
In patients with sarcoidosis we previously observed
significantly higher concentrations of GM-CSF in the
BAL fluid from patients with active sarcoidosis in com-
parison with the control group [28]. Recently, Patterson
Table 3 The mean spirometric values and the mean serum concentrations of examined cytokines in patients with progressive and











(mean ± SEM) (mean ± SEM) (mean ± SEM) (mean ± SEM) (mean ± SEM)








Age (years) 35.1 ± 1.9 36.2 ± 1.7 30.3 ± 1.5 35.7 ± 1.9 40.3 ± 2.3
32.5 (30.0–40.0) 34.0 (29.0–40.0) 29.0 (29.0–30.8) 33.5 (30.5–39.0) 40.0 (33.5–44.3)
FEV1 (% of
predicted)
87.1 ± 2.0 85.4 ± 2.4 87.7 ± 2.7 87.2 ± 1.8 83.1 ± 4.3
84.0 (81.0–92.0) 87.0 (80.0–94.0 90.0 (82.8–101.0) 85.0 (80.5–97.3) 85.0 (81.0–91.5)
FVC (% of
predicted)
96.8 ± 3.4 95.9 ± 2.7 100.2 ± 3.7 97.6 ± 2.8 90.7 ± 4.6
95.0 (88.0–108.0) 98.0 (91.0–103.0) 100.0 (96.0–105.5) 100.0 (89.5–104.0) 90.0 (82.8–101.0)
FEV1%VC (%) 75.6 ± 1.8 75.7 ± 1.2 77.0 ± 1.8 74.8 ± 1.5 75.8 ± 2.2
74.5 (70.0–82.0) 75.5 (71.0–79.0) 77.0 (74.0–80.0) 74.0 (70.5–77.5) 75.0 (68.8–83.5)
Angiopoeitin-2
(pg/ml)
239.1 ± 37.9 208.4 ± 41.5 355.6 ± 66.0* 206.0 ± 37.9 142.2 ± 42.2
220.0 (120.1–380.6) 169.0 (69.9–281.5) 361.7 (170.0–518.8) 178.3 (98.6–310.0) 89.0 (13.5–192.9)
Folistatin (pg/ml) 372.9 ± 51.9 346,456 ± 41.1 448.5 ± 59.1 328.8 ± 46.4 331.9 ± 62.2
348.8 (258.6–466.7) 304.6 (206.1–444.0) 406.5 (265.1–636.5) 296.6 (211.7–416.8) 357.9 (154.5–472.3)
GM-CSF (pg/ml) 28.8 ± 8.0 33.7 ± 5.7 45.4 ± 12.9 32.4 ± 6.0 20.1 ± 6.9
12.8 (10.3–32.0) 32.1 (7.6–56.0) 33.4 (10.5–88.2) 24.2 (8.3–52.1) 12.7 (2.5–34.6)
IL-8 (pg/ml) 28.4 ± 7.7 32.4 ± 4.4 47.7 ± 11.8 29.0 ± 4.6 20.4 ± 4.7
14.5 (13.7–22.7) 39.2 (11.9–48.7) 42.8 (15.1–85.7) 18.4 (13.3–46.6) 12.8 (10.7–28.8)
PDGF-BB (pg/ml) 5304.0 ± 786.5 5689.8 ± 772.3 5865.1 ± 856.4 5564.5 ± 863.6 5213.5 ± 1123.2
4591.3 (3054.5–6419.3) 5547.9 (2724.6–7594.7) 5044.5 (3544.5–8742.6) 4757.8 (2655.4–7972.2) 4575.5 (1536.6–8612.5)
PECAM-1 (pg/ml) 2537.3 ± 330.4 2456.6 ± 327.9 3126.1 ± 328.6 2377.3 ± 394.0 2175.5 ± 389.7
2469.8 (1502.1–3418.4) 2190.3 (1295.8–2854.1) 2596.1 (2323.9–4164.1) 1926.5 (1262.9–2818.9) 2290.7 (862.3–3340.9)
VEGF (pg/ml) 93.9 ± 13.7 84.9 ± 8.6 116.8 ± 21.5 87.9 ± 9.4 68.29 ± 9.6
79.9 (60.6–117.8) 87.6 (53.5–101.2) 98.8 (61.5–165.9) 87.9 (60.4–100.3) 62.7 (34.3–100.4)
*p < 0.05 sarcoidosis stage I vs sarcoidosis stage II and III
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et al. [29] have demonstrated a trend towards a signifi-
cant increase in GM-CSF serum concentrations in non-
fibrotic pulmonary sacroidosis, but not in fibrotic pul-
monary sarcoidosis. In present study, GM-CSF serum
concentration were significantly higher in IPF, but not in
sarcoidosis.
We noticed significant elevation of PDGF in serum of
IPF patients. Cao et al. [30] demonstrated that PDGF-BB
was located in pulmonary macrophages, fibroblasts and
vascular smooth muscle and endothelial cells, which
suggests the association of PDGF with fibroplasia and
the deposition of extracellular matrix, as well as vessel
remodeling in IPF. Our study stays in line with Wolff
et al. [31], who demonstrated significantly elevated
PDGF-BB levels in the BAL fluid from patients with al-
lergic alveolitis and fibrosing alveolitis, but decreased in
patients with sarcoidosis.
We observed an increased serum concentration of fol-
listatin in IPF, but not in sarcoidosis. Follistatin is effect-
ive in treating bleomycin -induced fibrosis by blocking
the actions of activin and TGF-beta [32]. Recently Myl-
lärniemi et al. found high-intensity follistatin staining in
the activated alveolar epithelium and parenchymal mac-
rophages obtained from IPF patients and suggest that
activin-B and follistatin may be useful as biomarkers of
IPF [33].
In our study serum concentrations of ANG-2 were
also similar in IPF, sarcoidosis and the controls. Serum
Ang-2 concentrations in stage I was higher than in stage
II and III patients with saroidosis. ANG-2 is an essential
factor for the vascular formation and is normally
expressed in the endothelial remodeling tissues, while it
is higher expressed during hypoxic processes [6]. Re-
cently a significant reduction of Ang-1 and increase of
Ang-2 protein expression in BAL fluid were detected in
IPF [34].
The low angiogenetic serum activity in our patients
with sarcoidosis may be, at least in part, explained by
the findings of Kambouchner et al. [35]. These authors
have not observed any angiogenesis in pulmonary sar-
coidosis. Namely CD31 immunolabelling, which recog-
nizes PECAM-1 on the blood micro-vessel network,
revealed that 85 % of intralobular sarcoid granulomas
were very poorly supplied by blood capillaries at the
outer edge of the peripheral fibrous ring, far from the
cellular compartment [35]. However, granulomas were
closely associated with lymphatics. This finding suggests
that a large majority of pulmonary sarcoid granulomas
can be considered ‘avascular’ [35].
We are not able to replicate some previously published
results of circulating cytokine alterations. Methodo-
logical differences may account for our different, yet not
contradictory findings: whereas many studies have
employed single-cytokine ELISA tests, used plasma or
culture supernatant samples, or had cohorts of newly di-
agnosed disease, we employed a multiplex assay, used
serum samples, and had a cohort of chronic disease.
Our study has limitations. A relatively small number
of patients, especially with IPF, was included into the
study and cytokines examinations were performed only
in serum, but not in BAL. The results of Diffusing Cap-
acity of the Lungs for Carbon Monoxide (DLCO) were
available only in few patients as no correlations were es-
timated between DLCO and cytokines concentrations.
No relationships were checked between the examined
angiogenic molecules and other potential markers of sar-
coidosis or IPF activity, for example: ACE (angiotensin
converting enzyme) or LDH (lactate dehydrogenase), as
no such data were available. It would be interesting to
compare results obtained from patients with IPF with
those at stage IV of sarcoidosis i.e., with fibrotic lung
changes, it was very difficult however to collect a suffi-
cient number of previously untreated sarcoid patients in
IV stage.
Conclusions
These results indicate that differences may exist in an-
giogenic activity between patients with parenchymal
lung diseases. In contrast to sarcoidosis, IPF is character-
ized by a higher serum concentration of different mole-
cules involved in the angiogenic processes.
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